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Background: Percutaneous iliofemoral venous stenting has been shown to be effective, safe, and durable in both
nonthrombotic iliac vein lesion (NIVL) and postthrombotic disease. A small fraction of stented limbs require reinter-
vention to correct stent malfunction. This manuscript examines the reasons for reintervention, types of procedures
performed, and outcome.
Methods: Femoro-ilio-caval stenting was performed in 1085 limbs over a 10 year period from 1997 to 2007 (NIVL/
postthrombotic limb ratio 1:1). Reinterventions were required in 137 limbs (13%) for non-occlusive stent malfunction.
Results: Median time of reintervention after the initial procedure was 15 months. Primary indication for reintervention
was stent abnormalities discovered on routine surveillance imaging in 31% of the limbs and residual/recurrent symptoms
after initial stenting in 69% of the limbs. Prevalent symptoms before reintervention were swelling (45%), pain (18%),
combination of pain and swelling (33%), and venous dermatitis/ulcer (15%). Seventy-seven percent of limbs required
only a single reintervention and 23% required two or more interventions. The type of reintervention could be broadly
categorized into four types: (1) cephalad stent extension to correct stent outflow problems; (2) caudad stent extension to
correct inflow problems; (3) balloon dilatation of stent stenoses; and (4) combinations. The types of stent inflow/outflow
lesions encountered were different in NIVL and postthrombotic limbs. In both groups, the external iliac vein segment
had a greater incidence of pathology than other stented venous segments during reintervention. A denovo stenotic lesion
of uncertain aetiology that occurred below an existing stent was also exclusive to the external iliac vein segment. Instent
restenosis (ISR) occurred in both subsets. Two types of ISR were encountered: (1) a ‘soft’ lesion probably due to reduced
flow channel lined by thrombus within the stent from inflow/outflow problems and (2) a ‘hard’ lesion that occurred
independently, was resistant to dilatation and tended to recur unlike the ‘soft’ lesion. Cumulative improvement in pain
and swelling at 18 months following intervention was 67% and 72%, respectively. Complete cumulative healing of venous
dermatitis/ulcer was 90% at 12 months post reintervention.
Conclusion: Venous stenting for chronic venous disease is largely trouble-free with only a small fraction of the stented
limbs requiring reinterventions. Reinterventions were performed to correct previously overlooked or new defects in
inflow, outflow and/or the stent. Reinterventions are worthwhile since they improve residual/recurrent symptoms in a
durable fashion. (J Vasc Surg 2009;49:511-8.)Percutaneous iliofemoral venous stenting has been
shown to be effective, safe, and durable in both nonthrom-
botic iliac vein lesion (NIVL) and postthrombotic disease.1
The objective of this study is to analyze those patients that
required reintervention after the initial procedure. This
information provides a window on the types of stent mal-
function that may occur, corrective actions required and
steps that may be taken during the initial procedure to
prevent them. The infrequency of post-stent interventions
is an indication that venous stenting in chronic venous
disease (CVD) is a relatively trouble-free procedure.
METHODS
A total of 1085 limbs underwent femoral-iliac-caval
venous stenting for chronic venous disease over a 10-year
period from 1997 to 2007. Disease was NIVL in 577 limbs
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doi:10.1016/j.jvs.2008.08.003and postthrombotic in 508 limbs. There were 31 (3%) stent
occlusions (4 of 31 had prior reinterventions), all of which
were in postthrombotic limbs; details have been described
elsewhere1 and excluded from this analysis. A total of 917
limbs (84%) had patent stents that did not require further
intervention during the follow-up period. Reinterventions
were required in 137 limbs (13%) for non-occlusive stent
malfunction, which is the subject of current analysis.
Symptom presentation, investigations, patient selec-
tion, stenting technique, and long-term outcome have
been described in detail previously.1-4 Self-expanding
braided stents were used in all but 18 limbs. Follow-up: the
patients were seen in the clinic at 6 weeks, 3 months, 6
months, and yearly thereafter. Limb pain was graded on a
visual analogue scale (VAS; 1-10).5 Limb edema was
graded 0 to 3; 0  none, 1  pitting, 2  ankledema, 3 
gross, involving the leg or limb. Stent patency and rate of
in-stent restenosis was assessed by venography1,3 at 6 to 12
weeks post-stent and annually thereafter. Patients were also
examined clinically and checked for stent patency on an ad
hoc basis for persistent or recurrent symptoms. Since the
last year of this study, duplex examination of the stent has
been increasingly used as a screen prior to venography to
assess stent patency/malfunction.
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was carried out according to the technique described by
Labropoulos.6 Briefly, stents were visualized in the recum-
bent position through the abdominal ‘window’ with ipsi-
lateral arm raised over the head. Stents were examined for
flow and velocities measured along the length of the stent.
Visible narrowing of the flow lumen and localized increase
in flow velocities were indicative of in-stent restenosis.
Because this technique of stent imaging was recently intro-
duced and has not been fully validated, pre-reintervention
assessment in the majority of cases in this series was based
on venography.
Ascending venography via pedal injection of contrast
was considered acceptable if adequate visualization of the
entire stent length was obtained. Otherwise transfemoral
venography was obtained for stent visualization. Visible
in-stent stenosis (50%), collaterals, and inflow or outflow
abnormalities were all considered evidence of stent mal-
function.
Intravascular ultrasound (IVUS)3,7 was the final diag-
nostic arbiter and was carried out if prior stent imaging
revealed evidence of stent malfunction, if limbs were symp-
tomatic, or both. Appropriate reintervention in the 137
limbs described herein was based on IVUS findings and was
carried out concurrently with IVUS.
Reintervention technique. A mid-thigh ipsilateral
antegrade femoral vein access2 under ultrasound guidance
with routine use of a sealant device (Vasoseal) at termina-
tion is employed. After an initial on-table venogram, IVUS
is used to examine the stent and adjoining inflow and
outflow segments. In-stent restenosis (ISR) is corrected by
high pressure (16 atm) balloon dilatation to appropriate
size, generally to the original nominal diameter of the
deployed stent. Overdilatation is discouraged to avoid frac-
ture (laser cut mesh stents) or foreshortening that may
result in stent separation at stent overlaps (braided stents).
Recoil of ISR and external compressions of the stent occur
to a variable degree following quick inflation/deflation of
the balloon and may be minimized by sustained pressure
dilatation for a minute or more until the balloon pressure
Table I. Details of 177 reintervention procedures in 137
Reintervention procedure
Balloon dilation
Caudad stent extension
Cephalad stent extension
Caudad  cephalad stent extensions
Balloon dilation  caudad stent extension
Balloon dilation  cephalad stent extension
Balloon dilation  caudad  cephalad stent extensions
Correct stent separation
Total
NIVL, Non-thrombotic iliac vein lesion.stabilizes at 16 atm without noticeable decay.Any defects in inflow or outflow segments to and from
the stent are corrected by additional stent deployment and
extension of the original stent assembly without skip areas.
Data analysis. Clinical features, operative details, and
follow-up data were contemporaneously entered into a
time-stamped electronics medical records program. Cur-
rent material is extracted from this database. A commer-
cially available statistical program (Graph Pad Prism for
Windows [version 3.0], GraphPad Software, San Diego,
Calif) was used for statistical analysis. Categorical variables
were analyzed by 2 test. Clinical outcome analysis was
plotted according to the Kaplan-Meier method. Log rank
test was used to compare cumulative curves. Results are
reported using P values. A P value of less than .05 was
considered significant.
RESULTS
A total of 76 of 577 (13%) postthrombotic limbs and
61 of 508 (12%) of NIVL limbs required reintervention
(P ns). Median age was 50 years (range, 15 to 83 years),
female to male ratio was 2.5:1, and left to right ratio was
3:1. Median time of first intervention after initial stent
deployment was 15months (range, 2 to 84months). There
was no difference in these demographics between NIVL
and postthrombotic limbs. Primary reason for reinterven-
tion was stent malfunction discovered on routine surveil-
lance imaging in 31% of limbs and residual/recurrent
symptoms in 69% of limbs. Presenting symptom prompting
reintervention in the latter subset was: pain (10%), swell-
ing (39%), combined pain/swelling (36%), and venous
dermatitis/ulcer (15%).
There were a total of 177 interventions in 137 limbs;
81 interventions in 61 NIVL limbs, and 96 reinterventions
in 76 postthrombotic limbs, respectively (P ns). Seventy-
seven percent of limbs required only a single reintervention,
18% two, and 5% three interventions each. There was no
difference in the single/multiple reintervention ratio be-
tween NIVL and postthrombotic limbs. The type of rein-
tervention could be categorized into four types: (1) ceph-
alad stent extension; (2) caudad stent extension; (3)
NIVL
(n  61 limbs)
Postthrombotic
(n  76
limbs) Total
29 46 75
4 8 12
25 20 45
5 7 12
1 6 7
11 9 20
5 0 5
1 0 1
81 96 177limbsballoon dilatation of stent stenoses; and (4) combinations.
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lesions beyond the original stent. Reintervention procedure
detail for NIVL and postthrombotic limbs is shown in
Table I.
Lesion types encountered during reintervention.
Intrastent lesions alone (ISR and stent compressions) oc-
curred in 75 of 177 (42%) reintervention procedures, with
concurrent extrastent stenoses in 32 (18%). Stenotic lesions
outside of the original stent (cephalad and/or caudad)
alone without stent involvement were seen in 70 of 177
(40%) reintervention procedures. Overall, extra stent ste-
noses occurred in 102 of 177 (58%) reinterventions. Seg-
ment distribution of lesion types encountered is shown in
Table II. The external iliac vein was most commonly in-
volved; IVC lesions including ISR of IVC stent extensions
were rare.
There were differences in the type of missed and new
extra-stent lesions between NIVL and postthrombotic
limbs. Because several specific lesion types in these two
subsets were recognized as such at variable times during
this experience, relative incidence data for individual lesion
types described below is not available.
In NIVL limbs, outflow lesions above the stent were
due to inadequate stent coverage of the original NIVL
stenosis at the junction of the iliac vein and inferior vena
cava. Reintervention was necessitated due to distal migra-
Fig 1. Distal migration of braided stent (left) because the stent
was not extended adequately into the inferior vena cava. The stent
is gradually “squeezed” distally by the constricting lesion, resulting
in recurrence. The stent should be extended well into the vena cava
to avoid this problem (right).
Table II. Lesion frequency by segment (n  128)*
Extrastent Intrastent Total
Inferior vena cava 17 10% 5 8% 22 9%
Common iliac
vein 54 31% 28 48% 82 35%
External iliac vein 78 45% 21 36% 99 43%
Common femoral
vein 24 14% 5 8% 29 13%
Total 173 100% 59 100% 232 100%
*Data missing in 9 of 137 limbs.tion or ‘squeezing’ of the braided self-expanding stent bythe lesion resulting in recurrence (Fig 1). Lesions detected
below the stent in NIVL limbs were one of three types: (1)
a previously missed distal NIVL stenosis (Fig 2, left); (2) a
previously overlooked retroinguinal stenosis (Fig 2, right);
Fig 2. Reintervention in a limb that continued to be symptomatic
following correction of proximal NIVL with a stent (left). A distal
lesion was discovered and stented. The distal lesion may be ob-
scured even on IVUS as it sits close to the hypogastric vein orifice.
Routine balloon ‘sizing’ (1 atm) of the entire iliac-femoral seg-
ment is recommended in all cases. A retroinguinal lesion (right)
uncovered by balloon ‘sizing.’ Venography alone is unreliable as
retroinguinal narrowing may be normally present in some patients
due to collapse of the vein in recumbent position in this location.
Fig 3. The nature of the denovo lesion is obscure but is exclu-
sively confined to the external iliac vein and occurs below a
previously placed stent after a period of time. It presents as a
smooth, tapered stenosis with no special characteristic features on
IVUS examination.and (3) a denovo lesion of uncertain etiology (Fig 3).
ing u
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noses or trabeculae in the inflow/outflow segments adjoin-
ing the stent that were new or missed during the original
procedure (Fig 4).
Intra-stent lesions were of similar type in NIVL and
postthrombotic disease: three distinct types of were found:
(1) a ‘soft’ ISR lesion (Fig 5); (2) a ‘hard’, more fibrous ISR
lesion (Fig 6); and (3) external compression of the stent
from inadequate ballooning or recoil of previously dilated
stenoses (Fig 7). The soft ISR lesion occurred in association
with inflow/outflow restriction into the stent and is likely
to be layered thrombus within the stent due to stagnant
flow. It was easily dilatable with near complete lesion
elimination and did not recur with correction of the flow
restricting lesion into or out of the stent. The hard ISR
lesion was more echogenic, often occurred independently,
was hard to dilate leaving considerable residue even after
Fig 4. Reintervention for residual symptoms in a postth
(left). A postthrombotic stenosis of the inferior vena ca
IVUS examination (middle). A stent was placed extend
Fig 5. Layering of thrombus within the stent due to ste
lesion (middle) responds well to balloon dilatation (
inflow/outflow problems for maintenance.repeated dilatations, and tended to recur.Outcome. There was no mortality or stent occlusion
(excluded) in this series. Deep vein thrombosis occurred in
seven limbs after reintervention (30 days for two limbs;
30 days for five limbs), all involving the venous tree
contralateral to the stented side.
Reinterventions improved presenting symptoms signif-
icantly (Table III) and was durable; cumulative improve-
ment in pain, swelling, and healing of venous dermatitis/
ulceration are shown in Table IV. There was no significant
difference between NIVL and postthrombotic subsets in
these cumulative results.
DISCUSSION
Venous stenting for symptomatic CVD has excellent
long-term patency and symptom relief.1 Reintervention is
infrequently required and when needed, appears to be
useful in maintaining patency and symptom relief. This
otic limb. On table venography appeared unremarkable
th fibrosis and trabeculae above the stent was found on
p to the renal vein orifice (right).
of inflow below the stent (left). This type of soft instent
), but requires simultaneous correction of associatedromb
va winosis
rightresulted in an astonishing 100% cumulative secondary stent
affected.
compressed to about 9 mm. Note the absence of ISR within
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in a total of 982 limbs at six years as previously reported.1
The difference between the two subsets is due to stent
occlusions. Though the overall incidence of stent occlu-
sions in the entire group of stented limbs is small (31 of
1085 or 3% non-cumulative), occlusions occur exclusively
in postthrombotic limbs (31 of 508 or 6%, non-cumulative),
two-thirds of them after recanalization of totally occlu-
ded postthrombotic veins. About a quarter of occluded
stents (23% [n  7]) were opened up by lysis, others
remained occluded because stent occlusion was not de-
tected in a timely fashion for successful lysis. It is now
possible to image iliac vein stents with duplex, allowing easy
surveillance and replacing the need for repetitive venogra-
phy. We currently perform routine stent surveillance in all
stented limbs the day after stent placement, at 6 weeks, and
yearly thereafter. A more frequent schedule in the early
poststent period (3, 6, and 10 weeks) in vulnerable post-
thrombotic stents (ie, stents with poor inflow/outflow or
after recanalization) may be warranted. Stents should also
be checked for patency/malfunction when symptoms recur
or when residual symptoms persist. When stent imaging
reveals inflow, outflow or in-stent abnormalities in such
cases, the need for intervention is clear. Experience indi-
cates that both venography and duplex imaging may be
unrevealing in some cases of stent malfunction. Our rec-
fibrosis of the lesion. A 16 mm diameter stent has beenFig 6. A ‘hard’ instent lesion without evident inflow/outflow
problems has a prediclection for the external iliac vein. The com-
mon iliac vein and the femoral vein are less frequently involved and
less profusely; the inferior vena cava portion of the stent is seldomFig 7. External compression of the stent by recoil/recurrent
the stent itself.
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symptomatic limbs even if imaging results are negative.
Some clinical judgment is required in deciding when to
perform IVUS/reinterventions when symptoms are slow to
resolve after initial stenting and imaging results are nega-
tive. Noticeable improvement in symptoms, particularly
that of pain indicating satisfactory stent function, is appar-
ent within days after stent deployment. Most ulcers and
dermatitis are resolved by 6 to 8 weeks after stenting.
Swelling may be slower to resolve, sometimes taking up to
6 months for complete resolution particularly (counterin-
tutively) in NIVL limbs. The reason for tardy resolution of
swelling in this subset is not clear. Such limbs with slow
clinical resolution may be watched for a period of time,
provided duplex imaging reveals a patent stent free of
lesions. A treadmill or stationary bicycle exercise program
(alternate days), with instructions to exercise the limb
gradually to the point of limb tiredness, appears to be
helpful in speeding resolution of symptoms. IVUS exami-
nation is scheduled if symptoms are not largely resolved by
6 months after initial stent placement, even if imaging
results at the time are non-revealing.
Ultrasound access for entry and routine use of a sealing
device at termination virtually eliminates access site compli-
cations. Mid-thigh entry provides for superior endovenous
maneuverability (torque and push) than other more distant
access locations (popliteal, contralateral femoral, internal
jugular), use of shorter length implements, and reduced
procedure times while leaving room above the tip of the
sheath to deploy stents in the femoral vein below the
inguinal ligament.
Lesions encountered during intervention were either
Table III. Symptom improvement following reinterventio
Relief of symptoms
Pre-interven
Median (ran
Pain (VAS scale)* (n  26) 6 (0-9)
Swelling Grade** (n  69) 3 (0-3)
VAS, visual analog scale.
*15 of 26 limbs had complete relief of pain.
**26 of 69 limbs had complete relief of swelling.
Table IV. Cumulative relief of presenting symptom
following reintervention
Symptom
Cumulative relief (n  limbs at risk)
6 months 12 months 18 months
Pain* (n  26) 100% (22) 75% (17) 67% (12)
Swelling** (n  69) 90% (68) 80% (57) 72% (48)
Dermatitis/ulcer***
(n  24) 90% (18) 90% (12) 70% (7)
Limbs at risk at various intervals are shown in parenthesis.
*Complete relief or improvement of 3 or more grades of VAS scale.
**Improvement of 1 or more swelling grade.
***Complete healing of dermatitis/ulcer.lesions missed during the original procedure or had devel-oped since. Most encountered in this experience appeared
to belong to the former category. Greater attention to
detail and proper technique during the original procedure
could have avoided many of them. Intravascular ultrasound
has an essential role in the initial stenting and in reinterven-
tions. Reliance on venography alone would have been
deficient as shown in the many illustrated examples.
Inadequate stent coverage of the NIVL lesion at the
junction of the iliac vein and inferior vena cava invariably
results in recurrence at this site (Fig 1).8 The proximal
NIVL3 can sometimes involve the lower end of the inferior
vena cava itself from a high aortic bifurcation,9 a feature
often masked in frontal venographic projections (Fig 8).
We have routinely extended the stent for 3-5 cm into the
vena cava tominimize this problem.8 In 1085 limbs stented
during a 10-year period, problems with contralateral limb
flow were rare (1%) and were successfully corrected when
they occurred.1 ISR of IVC stent extension was docu-
mented in only one limb included in this series. Distal
NIVL stenoses occur in as many as 64% ofNIVL cases,3 and
can be impervious to even IVUS in some cases (Fig 2).
Compressive lesions of the ilio-femoral vein behind the
inguinal ligament in NIVL as well as postthrombotic dis-
ease have been known for some time10 and are easily missed
as well. The genesis and nature of the denovo external iliac
Fig 8. The proximal NIVL can involve the distal end of the
inferior vena cava which can be masked in frontal projection (left)
but evident in lateral projection (right). IVUS is more reliable in
uncovering such lesions while minimizing radiation exposure.
Post-intervention
P valueMedian (range)
0 (0-8) .0004
1 (0-3) .0001n
tion
ge)vein stenosis is unknown.
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residual stenosis may be present with no visual focal cues to
indicate its presence on venography. Routine IVUS mea-
surement of the venous lumen may help identify diffuse
lesions. A lumen size (maximum diameter) less than 20mm
for the infrarenal vena cava, 16 mm for the common iliac
vein, 14 mm for the external iliac vein, and 12 mm for the
femoral vein in normal-sized adults are alertive of diffuse
stenoses. In combined NIVL/postthrombotic disease, ex-
cessive focal stenoses may develop at proximal, distal, or
retroinguinal NIVL locations in addition to postthrom-
botic stenoses elsewhere in the segment(s).10
Intra-stent lesions can occur in isolation or in combi-
nation with inflow/outflow problems. Like diffuse stenotic
lesions, external compressions of the stent from lesion
recoil are easily missed unless IVUS measurements are
taken. External compression of the stent by unrelieved
stenoses at the first instance is more common in postthrom-
botic limbs, particularly after recanalization of totally oc-
cluded veins. We are currently evaluating overdilation of
tough stenotic lesions and over sizing stents by one or two
sizes in an effort to minimize this problem. Rupture and
clinical bleeds are not a concern in venous stenting.1,11
Initial oversizing may be helpful in later aggressive dilata-
tion beyond resident size if stenoses were to recur. A
generous overlap of successive stents during the initial
deployment will help prevent foreshortening and stent
separation during such maneuvers. Initial deployment of
undersized stents for fear of rupturing the vein segment is
misguided and may result in poor symptom relief or worse
(Fig 9).
Though forming a large fraction in this reintervention
series, overall incidence of significant ISR is quite low in
veins (5%)1 compared with its high occurrence in the
arterial system. Significant ISR is nearly exclusive to post-
thrombotic limbs and the incidence is negligible (1%) in
Fig 9. Placement of undersized stents can result in persi
(left) or outright stent occlusion (right). In both cases,
size 16).NIVL pathology.1 It is not known whether the ISR lesionsare the same or similar in the two systems. The soft ISR
lesion is probably unique to venous stents. The advent of
large caliber high pressure balloons (16 to 18 atm) has
improved the outlook for treating stent stenoses whether
internal or external to the stent. Response to standard
pressure balloons (6 to 8 atm) was unsatisfactory.
The inclination to restrict stent assembly length to the
bare minimum to correct only major lesions is intuitive but
is counterproductive in the long run. The degree of metal
load per se does not seem to lead to vein occlusion in case of
stents11 and even from flow trap (filter) devices deployed in
thrombogenic limbs.12 The propensity to understent is
particularly strong when there is reluctance to extend the
stent into the inferior vena cava or below the inguinal
ligament into the femoral vein even when indicated. Stent
extensions in either direction is safe.13
The external iliac vein segment appears to be a weak
link in venous outflow of the limb with a propensity to
develop denovo stenoses, soft or hard in-stent stenoses, and
mask lesions that may pose potential problems. We have
become progressively more aggressive to extend the stent
from vena cava to the femoral vein to treat major andminor
lesions in bothNIVL and postthrombotic cases at the initial
procedure. Partial correction of lesions in iliac vein stenting
may result in residual or recurrent symptoms.
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